Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

R Pagliarini, W Shao, WR Sellers - EMBO reports, 2015 - embopress.org
R Pagliarini, W Shao, WR Sellers
EMBO reports, 2015embopress.org
A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and
maintain cancer cell proliferation and survival. While most cancers harbor multiple
oncogenic mutations, a wealth of preclinical and clinical data supports that many cancers
are sensitive to inhibition of single oncogenes, a concept referred to as 'oncogene addiction'.
Herein, we describe the clinical evidence supporting oncogene addiction and discuss
common mechanistic themes emerging from the response and acquired resistance to …
Abstract
A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and maintain cancer cell proliferation and survival. While most cancers harbor multiple oncogenic mutations, a wealth of preclinical and clinical data supports that many cancers are sensitive to inhibition of single oncogenes, a concept referred to as ‘oncogene addiction’. Herein, we describe the clinical evidence supporting oncogene addiction and discuss common mechanistic themes emerging from the response and acquired resistance to oncogene‐targeted therapies. Finally, we suggest several opportunities toward exploiting oncogene addiction to achieve curative cancer therapies.
embopress.org